Literature DB >> 22493294

Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis.

Sarah M Lo1, Murim Choi, Jun Liu, Dhanpat Jain, Rolf G Boot, Wouter W Kallemeijn, Johannes M F G Aerts, Farzana Pashankar, Gary M Kupfer, Shrikant Mane, Richard P Lifton, Pramod K Mistry.   

Abstract

Gaucher disease (GD), an inherited macrophage glycosphingolipidosis, manifests with an extraordinary variety of phenotypes that show imperfect correlation with mutations in the GBA gene. In addition to the classic manifestations, patients suffer from increased susceptibility to hematologic and nonhematologic malignancies. The mechanism(s) underlying malignancy in GD is not known, but is postulated to be secondary to macrophage dysfunction and immune dysregulation arising from lysosomal accumulation of glucocerebroside. However, there is weak correlation between GD/cancer phenotype and the systemic burden of glucocerebroside-laden macrophages. Therefore, we hypothesized that genetic modifier(s) may underlie the GD/cancer phenotype. In the present study, the genetic basis of GD/T-cell acute lymphoblastic lymphoma in 2 affected siblings was deciphered through genomic analysis. GBA gene sequencing revealed homozygosity for a novel mutation, D137N. Whole-exome capture and massively parallel sequencing combined with homozygosity mapping identified a homozygous novel mutation in the MSH6 gene that leads to constitutional mismatch repair deficiency syndrome and increased cancer risk. Enzyme studies demonstrated that the D137N mutation in GBA is a pathogenic mutation, and immunohistochemistry confirmed the absence of the MSH6 protein. Therefore, precise phenotype annotation followed by individual genome analysis has the potential to identify genetic modifiers of GD, facilitate personalized management, and provide novel insights into disease pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493294      PMCID: PMC3367875          DOI: 10.1182/blood-2011-10-386862

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Chemotherapy by slowing glucosphingolipid synthesis.

Authors:  N S Radin
Journal:  Biochem Pharmacol       Date:  1999-03-15       Impact factor: 5.858

2.  Gaucher disease: variability in phenotype among siblings.

Authors:  D Amato; T Stachiw; J T R Clarke; G E Rivard
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 3.  The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications.

Authors:  Daniel C Chung; Anil K Rustgi
Journal:  Ann Intern Med       Date:  2003-04-01       Impact factor: 25.391

Review 4.  Discrepancies between genotype and phenotype in hematology: an important frontier.

Authors:  E Beutler
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

Review 5.  The cellular pathology of lysosomal diseases.

Authors:  Timothy M Cox; M Begoña Cachón-González
Journal:  J Pathol       Date:  2012-01       Impact factor: 7.996

Review 6.  Gaucher disease: complexity in a "simple" disorder.

Authors:  Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2004 Sep-Oct       Impact factor: 4.797

7.  Abnormalities of cellular immunity and natural killer cells in Gaucher's disease.

Authors:  Y Burstein; V Zakuth; G Rechavi; Z Spirer
Journal:  J Clin Lab Immunol       Date:  1987-07

8.  Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages.

Authors:  Leonie A Boven; Marjan van Meurs; Rolf G Boot; Atul Mehta; Louis Boon; Johannes M Aerts; Jon D Laman
Journal:  Am J Clin Pathol       Date:  2004-09       Impact factor: 2.493

9.  The pathology of Gaucher disease.

Authors:  R E Lee
Journal:  Prog Clin Biol Res       Date:  1982

10.  Increased risk of cancer in patients with Gaucher disease.

Authors:  A Shiran; B Brenner; A Laor; I Tatarsky
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

View more
  12 in total

Review 1.  A Next Generation Multiscale View of Inborn Errors of Metabolism.

Authors:  Carmen A Argmann; Sander M Houten; Jun Zhu; Eric E Schadt
Journal:  Cell Metab       Date:  2015-12-17       Impact factor: 27.287

Review 2.  Exploring genetic modifiers of Gaucher disease: The next horizon.

Authors:  Brad A Davidson; Shahzeb Hassan; Eric Joshua Garcia; Nahid Tayebi; Ellen Sidransky
Journal:  Hum Mutat       Date:  2018-09-11       Impact factor: 4.878

Review 3.  Lysosomal diseases: diagnostic update.

Authors:  Bryan Winchester
Journal:  J Inherit Metab Dis       Date:  2014-04-08       Impact factor: 4.982

Review 4.  Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism.

Authors:  Pramod K Mistry; Tamar Taddei; Stephan vom Dahl; Barry E Rosenbloom
Journal:  Crit Rev Oncog       Date:  2013

5.  Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).

Authors:  Neal J Weinreb; David N Finegold; Eleanor Feingold; Zhen Zeng; Barry E Rosenbloom; Suma P Shankar; Dominick Amato
Journal:  Orphanet J Rare Dis       Date:  2015-05-22       Impact factor: 4.123

6.  Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes.

Authors:  Marissa Orenstein; Deborah Barbouth; Olaf A Bodamer; Neal J Weinreb
Journal:  Orphanet J Rare Dis       Date:  2014-03-31       Impact factor: 4.123

Review 7.  Novel Management and Screening Approaches for Haematological Complications of Gaucher's Disease.

Authors:  Pilar Giraldo; Marcio Andrade-Campos
Journal:  J Blood Med       Date:  2021-12-07

8.  Disease-drug pairs revealed by computational genomic connectivity mapping on GBA1 deficient, Gaucher disease mice.

Authors:  Tony Yuen; Jameel Iqbal; Ling-Ling Zhu; Li Sun; Aiping Lin; Hongyu Zhao; Jun Liu; Pramod K Mistry; Mone Zaidi
Journal:  Biochem Biophys Res Commun       Date:  2012-05-12       Impact factor: 3.575

9.  Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously.

Authors:  MSoledad Noya; Marcio Andrade-Campos; Pilar Irun; Laura López de Frutos; MFernanda López-Fernandez; Pilar Giraldo
Journal:  Clin Case Rep       Date:  2018-03-15

10.  Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.

Authors:  Shoshana Revel-Vilk; Maria Fuller; Ari Zimran
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.